SKINCARE business Evocutis has secured ten new contracts worth £280,000.
The Wetherby-based business, which focuses on advanced laboratory and clinical evaluations of skincare products for the health and cosmetic markets, said the contracts with well known global consumer healthcare companies also include early direct sales of its LabSkin living skin equivalent.
The contracts, ranging in size from £9,000 to £88,000 projects, are expected to be delivered over a two to six-month period.
Gwyn Humphreys, chief executive, of Evocutis, said: “I am delighted that the uptake of LabSkin is increasing and that our clients – all of which are household names – are seeing a clear benefit over alternative skin models available either commercially or in house. This is very positive in terms of future uptake of LabSkin and we are particularly pleased to see that our clients are using LabSkin successfully in their own laboratories.
“This validates our strategy of selling the product directly, as well as continuing to provide a full service offering to clients who require it.
“The significant combined contract value means that Evocutis is on course to meet management expectations and strengthens the company’s position in its ongoing search for a strategic partner, as announced in December.”